#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial
Body unavailable. Use the original source.
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial